| Not Yet Recruiting | A Phase I Study of PepGNP-ChikV in Healthy Volunteers NCT07394426 | Gylden Pharma Ltd | EARLY_Phase 1 |
| Not Yet Recruiting | Against Chikungunya Virus and Neonatal Infection NCT07190560 | Centre Hospitalier Universitaire de la Réunion | N/A |
| Not Yet Recruiting | VLA1553-403 Pregnancy Surveillance Study NCT07414524 | Valneva Austria GmbH | — |
| Withdrawn | A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children NCT07133178 | Valneva Austria GmbH | Phase 3 |
| Enrolling By Invitation | Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the NCT07254702 | Valneva Austria GmbH | — |
| Enrolling By Invitation | Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Va NCT07347002 | Valneva Austria GmbH | — |
| Active Not Recruiting | Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for P NCT07163845 | Valneva Austria GmbH | — |
| Enrolling By Invitation | Xpert® Tropical Fever Test on GeneXpert® Edge X System NCT07520279 | Cepheid | — |
| Not Yet Recruiting | Chikungunya Virus Detection in Semen NCT06983548 | University Hospital, Toulouse | N/A |
| Recruiting | Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Sever NCT06928753 | Centre Hospitalier Universitaire de la Réunion | Phase 4 |
| Not Yet Recruiting | Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-b NCT06859619 | University Hospital, Montpellier | N/A |
| Withdrawn | A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) NCT06028841 | Valneva Austria GmbH | Phase 3 |
| Completed | A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years NCT06106581 | Valneva Austria GmbH | Phase 2 |
| Active Not Recruiting | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination NCT06007183 | Bavarian Nordic | Phase 3 |
| Active Not Recruiting | Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) NCT04838444 | Valneva Austria GmbH | Phase 3 |
| Completed | Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Hea NCT04786444 | Valneva Austria GmbH | Phase 3 |
| Completed | Phase 1 Study of SAR440894 vs Placebo NCT04441905 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate i NCT04546724 | Valneva Austria GmbH | Phase 3 |
| Completed | Consequences of a Maternal-fetal Chikungunya Virus Infection NCT04909411 | Centre Hospitalier Universitaire de la Réunion | N/A |
| Terminated | Yoga for Chronic Chikungunya NCT04455919 | Centre Hospitalier Universitaire de la Guadeloupe | N/A |
| Completed | Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) NCT03807843 | Themis Bioscience GmbH | Phase 2 |
| Completed | Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005 NCT03635086 | Themis Bioscience GmbH | Phase 2 |
| Completed | Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults NCT03483961 | Bavarian Nordic | Phase 2 |
| Completed | Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia NCT03631719 | Universidad de Antioquia | — |
| Completed | Phase I Trial of Measles Vectored Chikungungya Vaccine NCT03028441 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine NCT02861586 | Themis Bioscience GmbH | Phase 2 |
| Completed | Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults NCT02562482 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sam NCT02553369 | University Hospital Center of Martinique | — |
| Unknown | Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins NCT02230163 | Centre Hospitalier Universitaire de la Guadeloupe | Phase 1 / Phase 2 |
| Completed | Chikungunya Virus Vaccine Trial in Healthy Adults NCT01489358 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |